Clinical Trial Update: Radium-223 in Biochemically Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Radium-223 for biochemically recurrent prostate cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Biochemical Recurrent Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING